Lbp Am Sa Sells 64,443 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Lbp Am Sa reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 97.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,641 shares of the medical research company’s stock after selling 64,443 shares during the quarter. Lbp Am Sa’s holdings in Thermo Fisher Scientific were worth $954,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $2,909,524,000. Capital World Investors lifted its stake in shares of Thermo Fisher Scientific by 10.0% in the 1st quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock valued at $7,842,762,000 after acquiring an additional 1,231,059 shares during the last quarter. International Assets Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 61,995.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock worth $535,923,000 after buying an additional 1,008,045 shares during the period. Veritas Asset Management LLP lifted its holdings in Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock worth $898,175,000 after buying an additional 697,383 shares during the period. Finally, Winslow Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $333,786,000. 89.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Jefferies Financial Group reiterated a “buy” rating and set a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Robert W. Baird boosted their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft boosted their price objective on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Finally, HSBC boosted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Stock Down 1.6 %

Thermo Fisher Scientific stock traded down $9.87 during mid-day trading on Friday, reaching $611.90. 683,619 shares of the company were exchanged, compared to its average volume of 1,559,618. The business has a fifty day moving average of $564.89 and a 200 day moving average of $567.58. The firm has a market cap of $233.57 billion, a P/E ratio of 39.88, a PEG ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $5.15 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The disclosure for this sale can be found here. Insiders have sold a total of 33,084 shares of company stock valued at $19,767,092 in the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.